Expression and clinical significance of muti-drug resistance factors:P-gp,GST-?,TOPO? in lung cancer
- VernacularTitle:耐药表型P-gp,GST-?,及TOPOⅡ的表达与Ki67在肺癌中的表达及其临床意义
- Author:
Le PENG
- Publication Type:Journal Article
- Keywords:
Lung cancer;
MDR;
Immunohistochemistry
- From:
Journal of Chongqing Medical University
1986;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To examine the expression of P-gp,GST-?,TOPO? and Ki67 in lung cancer and study the clinical relationship of P-gp,GST-?,TOPO?and Ki67 Co-expression in lung cancer.Methods: The expression of P-gp,GST-?,TOPO? in 52 cases of lung cancer without chemotherapy was detected before operation by immunohistochemical staning.Results: The positive rates of P-gp,GST-?,TOPO?,Ki67 were respectively 73%,80.5%,62.5%,23.7%.The P-gp,GST-? expression was correlated with the histology and differentiation,The expression of TOPO? was obviously lower in adenocarcinoma than in other typers of lung cancers;The coexpression rate of more than one MDR gene production appareatly exceeded individual expression rate.The expression of P-gp,GST-?,TOPO? was not correlated with the expression of Ki67.Conclusion: P-gp,GST-?,TOPO? can be expressed in different types of lung cancers and with different expression levels,They are all correlated with multidrug resistance of lung cancer,Thus,they can be regarded as a valuable indicators for clinical chemotherapy and for prognosis in lung cancer patients.
